CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed
Drug / intervention
Olanzapinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00088036
NCT00088036Phase 3Completed
CompareCT.gov

Efficacy and Safety of Olanzapine in Patients With Borderline Personality Disorder: A Randomized Double-Blind Comparison With Placebo

Eli Lilly and Company·interventional·Posted Jul 21, 2004·Updated Jul 24, 2006

In Brief

A Phase 3 clinical trial evaluating Olanzapine for Borderline Personality Disorder. Completed, across 15 sites in 5 countries.

Detailed Summary

The purpose of the protocol is to evaluate the efficacy and safety of olanzapine compared with placebo in patients with Borderline Personality Disorder (BPD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBorderline Personality Disorder
CountriesArgentina, Poland, Romania, Turkey (Türkiye), United States
Collaborators--

Timeline

Phase 3CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 21, 2004
Enrollment StartFeb 1, 2004
Study CompletionJan 1, 2006
TodayJul 2, 2026
Posted 21.9 years ago

Interventions

Olanzapinedrug